This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

linagliptin (Trajenta®)

Reference No. 1667

Publication date:

Last review date:

Appraisal information

linagliptin (Trajenta®) 5 mg film-coated tablet

Company: Boehringer Ingelheim Ltd
BNF category: Endocrine system
NMG meeting date: 20/02/2013
AWMSG meeting date: 20/03/2013
Submission Type: Full Submission
Status: Recommended
Advice No: 0513
Ratification by Welsh Government: 22/05/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

Linagliptin (Trajenta®) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; as combination therapy • in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control; • in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; and • in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary